Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>The Ensign Group, Inc.'s latest quarterly results reveal a mixture of strengths and challenges as the company navigates the post-acute care market.</li>
<li>In the third quarter, The Ensign Group reported record performance in several key areas, driven largely by strong operational execution and clinical outcomes.</li>
<li>The company's same-store and transitioning occupancy rates reached all-time highs, alongside notable increases in skilled days and Medicare revenue.</li>
</ul>


The Ensign Group, Inc.'s latest quarterly results reveal a mixture of strengths and challenges as the company navigates the post-acute care market.
In the third quarter, The Ensign Group reported record performance in several key areas, driven largely by strong operational execution and clinical outcomes.
The company's same-store and transitioning occupancy rates reached all-time highs, alongside notable increases in skilled days and Medicare revenue.


The Ensign Group: Could Its Expansion Blueprint Trigger the Next Big Stock Rally?

<ul>
<li>The Ensign Group, Inc. reported a strong performance for the first quarter of fiscal year 2025, reflected in various all-time high metrics which illustrate its robust growth and operational efficiency.</li>
<li>Key positives include substantial increases in both occupancy rates—same-store and transitioning operations reached 82.6% and 83.5%, respectively.</li>
<li>Moreover, the company saw significant growth in skilled census and managed care census across its operations, driven by effective local leadership and improved clinical outcomes.</li>
</ul>


The Ensign Group, Inc. reported a strong performance for the first quarter of fiscal year 2025, reflected in various all-time high metrics which illustrate its robust growth and operational efficiency.
Key positives include substantial increases in both occupancy rates—same-store and transitioning operations reached 82.6% and 83.5%, respectively.
Moreover, the company saw significant growth in skilled census and managed care census across its operations, driven by effective local leadership and improved clinical outcomes.


ENSGs Geographic Expansion And Improving Market Presence Is An Important Growth Lever!

<ul>
<li>The Ensign Group's recent quarterly earnings presents a comprehensive picture of the company's operational and financial performance, accompanied by strategic insights for future growth.</li>
<li>Here's an investment thesis and results summary reflecting both the positive aspects and potential challenges.</li>
<li>The company's performance highlights strong operational momentum characterized by record clinical and financial results.</li>
</ul>


The Ensign Group's recent quarterly earnings presents a comprehensive picture of the company's operational and financial performance, accompanied by strategic insights for future growth.
Here's an investment thesis and results summary reflecting both the positive aspects and potential challenges.
The company's performance highlights strong operational momentum characterized by record clinical and financial results.


The Ensign Group: An Insight Into Its Growth Through Acquisitions & Market Expansion!

External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

<ul><li>Ensign Group is the largest skilled nursing facility operator in the US, specializing in acquiring and improving underperforming facilities</li><li>Ensign's workforce system empowers facility-level leaders for quick decision-making, allowing for efficient operations and rapid turnarounds</li><li>Ensign's strategic focus on efficiency, despite short patient stays, has positioned them for continued growth and success in a fragmented market.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Ensign Group is the largest skilled nursing facility operator in the US, specializing in acquiring and improving underperforming facilitiesEnsign's workforce system empowers facility-level leaders for quick decision-making, allowing for efficient operations and rapid turnaroundsEnsign's strategic focus on efficiency, despite short patient stays, has positioned them for continued growth and success in a fragmented market.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Ensign Group Inc (ENSG) - Wednesday, Nov 13, 2024

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).</li>
<li>SPX is pulling back after hitting all-time highs; the gap at 6750-6772 is short-term support, and it is a clear sign bulls remain in control if this gap remains unfilled.</li>
<li>We will stay near-term bullish as long as the 3+ month uptrend continues (currently at ~6675). Additional supports include 6550-6569, 6480-6520, 6450, 6400-6410, 6340-6360, 6290, 6200, and 6100-6150</li>
</ul>


We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).
SPX is pulling back after hitting all-time highs; the gap at 6750-6772 is short-term support, and it is a clear sign bulls remain in control if this gap remains unfilled.
We will stay near-term bullish as long as the 3+ month uptrend continues (currently at ~6675). Additional supports include 6550-6569, 6480-6520, 6450, 6400-6410, 6340-6360, 6290, 6200, and 6100-6150


Magnificent Seven's Turn to Shine; Buy Pullbacks to 3+ Month SPX Uptrend and 50-Day MA

United States

Ensign Group, Inc. operates facilities offering nursing and rehabilitative care services in multiple states. The Company provides a broad spectrum of nursing and assisted living services, physical, occupational and speech therapies, and other rehabilitative and healthcare services, for both long-term residents and short-stay rehabilitation patients.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ensign Group (ENSG US)

The Ensign Group: Could Its Expansion Blueprint Trigger the Next Big Stock Rally?

The Ensign Group, Inc.'s latest quarterly results reveal a mixture of strengths and challenges as the company navigates the post-acute care market.

Baptista Research

ENSGs Geographic Expansion And Improving Market Presence Is An Important Growth Lever!

Key positives include substantial increases in both occupancy rates—same-store and transitioning operations reached 82.6% and 83.5%, respectively.

Baptista Research

The Ensign Group: An Insight Into Its Growth Through Acquisitions & Market Expansion!

The Ensign Group's recent quarterly earnings presents a comprehensive picture of the company's operational and financial performance, accompanied...

Baptista Research

Ensign Group Inc (ENSG) - Wednesday, Nov 13, 2024

Ensign Group is the largest skilled nursing facility operator in the US, specializing in acquiring and improving underperforming facilities

Value Investors Club (VIC)

Magnificent Seven's Turn to Shine; Buy Pullbacks to 3+ Month SPX Uptrend and 50-Day MA

Magnificent Seven's $MAGS Turn to Shine; Buy Pullbacks to 3+ Month $SPX Uptrend and 50-day MA, currently 6655-6680. Buys: $AAPL $TSLA $NVDA $GOOGL...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)